
# FIDELIZADE SEGUROS DESDE 1808

## Consolidated 2Q 2023 Solvency II Lisbon, September 4<sup>th</sup>, 2023

Unaudited figures

### **Solvency II ratio**

Fidelidade's consolidated 2Q2023 Solvency II ratio was 173%, a 6,9p.p. decrease compared to March 2022. Own funds declined 2,1% relative to the end of 1Q2023 and closed the semester at 3.229M€, while capital requirement reached 1.864M€, a 1,8% rise.



#### Fidelidade Consolidated Solvency II Ratio

The main driver behind the reduction in the Solvency II ratio was the 119M€ regular dividend disbursed in May. It accounted for approximately 6,4p.p. of the 6,9p.p. decline. This dividend payment is the first one Fidelidade has made since Fosun's acquisition in 2014. It represents a payout ratio of about 54% and is part of Fidelidade's dividend policy. As previously explained, this policy is subject to a governance process which has several controls in place, including the requirement that the Solvency II ratio exceeds the lower-bound of the 150-180% range and the two main shareholders joint approval of dividends.

#### **Outlook**

Fidelidade management remains committed to maintaining the Solvency ratio comfortably in the 150% to 180% range defined in the company's Risk Appetite Framework.

Going forward, balance sheet optimization continues to be an ongoing priority. The effort to derisk the Life-Financial product offering remains undeterred, adjusting its execution to lever current market conditions. In addition, measures related to subsidiaries are also considered. As part of Fidelidade's strategy to support the growth of its portfolio companies while further enhancing its capital efficiency, the Board of Directors is currently analysing the opportunity of a potential listing of Luz Saúde, in which Fidelidade will retain its majority shareholding. At this stage no formal decision has been taken and further details will be provided in due course.